M Jahangir Alam

List of Publications by Year
in descending order

74 papers	1,487 citations	361413 20 h-index	345221 36 g-index
75 all docs	75 docs citations	75 times ranked	1762 citing authors

#	Article	IF	Citations
1	FKS Mutant Candida glabrata: Risk Factors and Outcomes in Patients With Candidemia. Clinical Infectious Diseases, 2014, 59, 819-825.	5.8	147
2	Resistance class 1 integron in clinical methicillinâ€resistant Staphylococcus aureus strains in southern China, 2001â€“2006. Clinical Microbiology and Infection, 2011, 17, 714-718.	6.0	127
3	First report of class 2 integron in clinical Enterococcus faecalis and class 1 integron in Enterococcus faecium in South China. Diagnostic Microbiology and Infectious Disease, 2010, 68, 315-317.	1.8	95
4	Prevalence and antimicrobial resistance of Salmonella in retail foods in northern China. International Journal of Food Microbiology, 2010, 143, 230-234.	4.7	87
5	Comparison of the T2Dx instrument with T2Candida assay and automated blood culture in the detection of Candida species using seeded blood samples. Diagnostic Microbiology and Infectious Disease, 2013, 77, 324-326.	1.8	71
6	Impact on toxin production and cell morphology inClostridium difficileby ridinilazole (SMT19969), a novel treatment forC. difficileinfection. Journal of Antimicrobial Chemotherapy, 2016, 71, 1245-1251.	3.0	54
7	Investigation of potentially pathogenic Clostridium difficile contamination in household environs. Anaerobe, 2014, 27, 31-33.	2.1	50
8	Treatment of Candida famata bloodstream infections: case series and review of the literature. Journal of Antimicrobial Chemotherapy, 2013, 68, 438-443.	3.0	49
9	Studies on pathogenic Vibrio parahaemolyticus during a warm weather season in the Seto Inland Sea, Japan. Environmental Microbiology, 2003, 5, 706-710.	3.8	46
10	Evaluation of Portability and Cost of a Fluorescent PCR Ribotyping Protocol for Clostridium difficile Epidemiology. Journal of Clinical Microbiology, 2015, 53, 1192-1197.	3.9	46
11	Community Environmental Contamination of Toxigenic Clostridium difficile. Open Forum Infectious Diseases, 2017, 4, ofx018.	0.9	44
12	Application of in situ loop-mediated isothermal amplification method for detection of Salmonella in foods. Food Control, 2011, 22, 438-444.	5.5	43
13	Rapid detection of food-borne Listeria monocytogenes by real-time quantitative loop-mediated isothermal amplification. Food Science and Biotechnology, 2012, 21, 101-106.	2.6	40
14	In the Endemic Setting, Clostridium difficile Ribotype 027 Is Virulent But Not Hypervirulent. Infection Control and Hospital Epidemiology, 2015, 36, 1318-1323.	1.8	38
15	Development of a fimY-based loop-mediated isothermal amplification assay for detection of Salmonella in food. Food Research International, 2012, 45, 1011-1015.	6.2	37
16	The respiratory burst activity and expression of catalase in white shrimp, Litopenaeus vannamei, during long-term exposure to pH stress. Ecotoxicology, 2012, 21, 1609-1616.	2.4	30
17	Cadazolid for the treatment of Clostridium difficile. Expert Opinion on Investigational Drugs, 2017, 26, 509-514.	4.1	24
18	Novel antibiotics in development to treat Clostridium difficile infection. Current Opinion in Gastroenterology, 2017, 33, 1-7.	2.3	24

#	Article	IF	Citations
19	Multiplex Real-Time PCR Method for Simultaneous Identification and Toxigenic Type Characterization of Clostridium difficile From Stool Samples. Annals of Laboratory Medicine, 2015, 35, 306-313.	2.5	23
20	Inhibition of Biofilm Formation by Esomeprazole in Pseudomonas aeruginosa and Staphylococcus aureus. Antimicrobial Agents and Chemotherapy, 2012, 56, 4360-4364.	3.2	22
21	PCR ribotypes of Clostridioides difficile across Texas from 2011 to 2018 including emergence of ribotype 255. Emerging Microbes and Infections, 2020, 9, 341-347.	6.5	21
22	Acquisition of Clostridium difficile Colonization and Infection After Transfer From a Veterans Affairs Hospital to an Affiliated Long-Term Care Facility. Infection Control and Hospital Epidemiology, 2017, 38, 1070-1076.	1.8	21
23	Evaluation of a shoe sole UVC device to reduce pathogen colonization on floors, surfaces and patients. Journal of Hospital Infection, 2018, 98, 96-101.	2.9	20
24	Rapid Detection of Genetically Modified Ingredients in Soybean Products by Real-Time Loop-Mediated Isothermal Amplification. Journal of Food and Nutrition Research (Newark, Del), 2014, 2, 363-368.	0.3	20
25	Clostridioides (Formerly Clostridium) difficile Infection During Hospitalization Increases the Likelihood of Nonhome Patient Discharge. Clinical Infectious Diseases, 2019, 68, 1887-1893.	5.8	18
26	Reduced Susceptibility to Metronidazole Is Associated With Initial Clinical Failure in Clostridioides difficile Infection. Open Forum Infectious Diseases, 2021, 8, ofab365.	0.9	18
27	Antibiotic Resistance and Growth of the Emergent Pathogen Escherichia albertii on Raw Ground Beef Stored under Refrigeration, Abuse, and Physiological Temperature. Journal of Food Protection, 2013, 76, 124-128.	1.7	17
28	Efficacy, Safety, Pharmacokinetics, and Microbiome Changes of Ibezapolstat in Adults with Clostridioides difficile Infection: A Phase 2a Multicenter Clinical Trial. Clinical Infectious Diseases, 2022, 75, 1164-1170.	5.8	17
29	Prevalence and Persistence of Salmonella in Cohorts of Feedlot Cattle. Foodborne Pathogens and Disease, 2011, 8, 781-789.	1.8	15
30	Environmental transmission of Clostridioides difficile ribotype 027 at a long-term care facility; an outbreak investigation guided by whole genome sequencing. Infection Control and Hospital Epidemiology, 2018, 39, 1322-1329.	1.8	14
31	Epidemic Clostridioides difficile Ribotype 027 Lineages: Comparisons of Texas Versus Worldwide Strains. Open Forum Infectious Diseases, 2019, 6, ofz013.	0.9	14
32	In Vitro Activity of Omadacycline, a New Tetracycline Analog, and Comparators against Clostridioides difficile. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	14
33	A pilot study to assess bacterial and toxin reduction in patients with Clostridium difficile infection given fidaxomicin or vancomycin. Annals of Clinical Microbiology and Antimicrobials, 2016, 15, 22.	3.8	13
34	Activity of Hospital Disinfectants against Vegetative Cells and Spores of Clostridioides difficile Embedded in Biofilms. Antimicrobial Agents and Chemotherapy, 2019, 64, .	3.2	13
35	Eosinopenia and Binary Toxin Increase Mortality in Hospitalized Patients With Clostridioides difficile Infection. Open Forum Infectious Diseases, 2020, 7, ofz552.	0.9	13
36	Evaluating the Effects of Surotomycin Treatment on Clostridium difficile Toxin A and B Production, Immune Response, and Morphological Changes. Antimicrobial Agents and Chemotherapy, 2016, 60, 3519-3523.	3.2	12

#	Article	IF	Citations
37	Characterization of Clostridioides difficile ribotypes in domestic dogs in Rio de Janeiro, Brazil. Anaerobe, 2019, 58, 22-29.	2.1	12
38	A randomized, double-blind, placebo-controlled, single and multiple ascending dose Phase 1 study to determine the safety, pharmacokinetics and food and faecal microbiome effects of ibezapolstat administered orally to healthy subjects. Journal of Antimicrobial Chemotherapy, 2020, 75, 3635-3643.	3.0	12
39	Accelerate PhenoTest^{TM} BC Kit Versus Conventional Methods for Identification and Antimicrobial Susceptibility Testing of Gram-Positive Bloodstream Isolates: Potential Implications for Antimicrobial Stewardship. Annals of Pharmacotherapy, 2018, 52, 754-762.	1.9	11
40	Systems biology evaluation of refractory Clostridioides difficile infection including multiple failures of fecal microbiota transplantation. Anaerobe, 2021, 70, 102387.	2.1	8
41	Assessment of Kidney Injury as a Severity Criteria for Clostridioides Difficile Infection. Open Forum Infectious Diseases, 2020, 7, ofaa476.	0.9	8
42	A novel method for imaging the pharmacological effects of antibiotic treatment on Clostridium difficile. Anaerobe, 2016, 40, 10-14.	2.1	7
43	In vitro activity of eravacycline against common ribotypes of Clostridioides difficile. Journal of Antimicrobial Chemotherapy, 2020, 75, 2879-2884.	3.0	7
44	Visualization of fidaxomicin association with the exosporium layer of Clostridioides difficile spores. Anaerobe, 2021, 69, 102352.	2.1	7
45	Genetic Variations in Shiga Toxinâ€Producing Abilities of Bovine and Human Escherichia coli O157:H7. Zoonoses and Public Health, 2011, 58, 185-191.	2.2	6
46	Clostridioides difficile ribotypes isolated from domestic environment and from patients in Bangladesh. Anaerobe, 2019, 56, 88-90.	2.1	6
47	Isolation and characterisation of carbapenem-resistant Pseudomonas aeruginosa from hospital environments in tertiary care hospitals in Dhaka, Bangladesh. Journal of Global Antimicrobial Resistance, 2022, 30, 31-37.	2.2	6
48	Host Factors and Clinical Outcomes of Candida Colonization in Critically Ill Patients. Mycopathologia, 2015, 179, 87-93.	3.1	5
49	Molecular epidemiology of Clostridioides difficile in domestic dogs and zoo animals. Anaerobe, 2019, 59, 107-111.	2.1	5
50	Functional and Metagenomic Evaluation of Ibezapolstat for Early Evaluation of Anti-Recurrence Effects in Clostridioides difficile Infection. Antimicrobial Agents and Chemotherapy, 2022, 66, .	3.2	5
51	Comparative clinical outcomes evaluation of hospitalized patients infected with Clostridioides difficile ribotype 106 vs. other toxigenic strains. Anaerobe, 2021, 72, 102440.	2.1	4
52	LB7. A Randomized, Blinded, Placebo- and Vancomycin-Controlled, First-In-Human (FIH) Study of the Safety, Pharmacokinetics (PK), and Fecal Microbiome Effects of ACX-362E, a Novel Anti-Clostridial DNA Polymerase IIIC (polIIIC) Inhibitor. Open Forum Infectious Diseases, 2019, 6, S995-S996.	0.9	3
53	Molecular epidemiology of toxigenic Clostridioides difficile isolates from hospitalized patients and the hospital environment in Dhaka, Bangladesh. Anaerobe, 2020, 61, 102081.	2.1	3
54	Multi-country surveillance of Clostridioides difficile demonstrates high prevalence of spores in non-healthcare environmental settings. Anaerobe, 2022, 75, 102543.	2.1	3

#	Article	IF	Citations
55	A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment. Journal of Visualized Experiments, 2017, , .	0.3	2
56	688. In Vitro Activity of Eravacycline, a New Tetracycline Analog, and Comparators Against the Six Most Commonly Isolated Ribotypes of Clostridioides difficile. Open Forum Infectious Diseases, 2019, 6, S312-S313.	0.9	2
57	Whole genome sequencing data of a clinical Enterococcus gallinarum strain EGR748 from Sabah, Malaysia. Data in Brief, 2020, 33, 106370.	1.0	2
58	710. Increased Clinical Failure Rates Associated with Reduced Metronidazole Susceptibility in Clostridioides difficile. Open Forum Infectious Diseases, 2018, 5, S255-S256.	0.9	1
59	1720. Isolation and Characterization of Candida auris From an Active Surveillance System in Texas. Open Forum Infectious Diseases, 2019, 6, S630-S630.	0.9	1
60	2580. Serial Microbiome Analysis in a Patient with Multiple Failed Fecal Microbiome Transplantations. Open Forum Infectious Diseases, 2019, 6, S896-S896.	0.9	1
61	1052. Characterisation of the DNA binding properties of ridinilazole, a selective antibiotic currently in phase III trials for the treatment of Clostridioides difficile. Open Forum Infectious Diseases, 2021, 8, S617-S617.	0.9	1
62	Draft genome sequence data of a clinical Enterococcus faecalis isolate SHH039 from a patient with cholecystitis from a tertiary care hospital in Sabah, Malaysia. Data in Brief, 2022, 41, 108019.	1.0	1
63	Clinical use comparison of a semiautomated PCR with fluorescent ribotyping for typing of Clostridium difficile. Archives of Microbiology, 2017, 199, 317-323.	2.2	0
64	Antimicrobial Susceptibility Assessment of Clinical Clostridium difficile Isolates in Relation to CRISPR-Cas. Open Forum Infectious Diseases, 2017, 4, S132-S132.	0.9	0
65	First Environmental Investigation of Toxigenic Clostridium difficile at a Large Hospital in Bangladesh. Open Forum Infectious Diseases, 2017, 4, S406-S406.	0.9	0
66	471. Prevalence and Characteristics of Clostridioides difficile Infection in Bangladesh. Open Forum Infectious Diseases, 2018, 5, S176-S176.	0.9	0
67	510. First Environmental Investigation of Toxigenic Clostridium difficile Strains in Texas Hospitals. Open Forum Infectious Diseases, 2018, 5, S189-S189.	0.9	0
68	2391. Increased Risk of Systemic Infections with Multidrug-Resistant Organisms in Patients with Severe Clostridioides difficile Infection. Open Forum Infectious Diseases, 2019, 6, S825-S825.	0.9	0
69	2398. Effect of Eosinopenia and Binary Toxin on Clostridioides difficile Infection Clinical Outcomes. Open Forum Infectious Diseases, 2019, 6, S828-S828.	0.9	0
70	2410. Molecular Characteristics of Environmental Clostridioides difficile From a Large Texas Hospital. Open Forum Infectious Diseases, 2019, 6, S832-S832.	0.9	0
71	2581. An Invertebrate Model to Study Gut Microbiome Dysbiosis. Open Forum Infectious Diseases, 2019, 6, S896-S897.	0.9	0
72	1197. Inhibitory Effect of Ursodeoxycholic Acid on Clostridioides difficile Growth. Open Forum Infectious Diseases, 2020, 7, S621-S621.	0.9	0

#	Article	IF	Citations
73	784. A Novel Method to Assess Virulence of Clostridioides difficile: Focus on C. difficile Ribotype 106. Open Forum Infectious Diseases, 2020, 7, S436-S437.	0.9	0
74	701. An Open-label Phase 2a Study of Ibezapolstat, a Unique Gram-positive Selective Spectrum (GPSS) Antibiotic, for Patients with Clostridioides difficile Infection. Open Forum Infectious Diseases, 2021, 8, S451-S451.	0.9	0